{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.70","upperLimit":"4.04","value":"2.37"},{"groupId":"OG001","lowerLimit":"5.04","upperLimit":"8.43","value":"6.74"}]}],"title":"Functional Scale: Physical Functioning Score (Change from Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.91","upperLimit":"1.84","value":"-0.03"},{"groupId":"OG001","lowerLimit":"-8.22","upperLimit":"-4.40","value":"-6.31"}]}],"title":"Symptom Scale: Fatigue Score (Change from Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"4.92","value":"2.87"},{"groupId":"OG001","lowerLimit":"-6.67","upperLimit":"-2.48","value":"-4.58"}]}],"title":"Individual Symptom Item: Appetite Loss Score (Change from Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.67","upperLimit":"4.98","value":"3.32"},{"groupId":"OG001","lowerLimit":"5.70","upperLimit":"9.07","value":"7.38"}]}],"title":"Global Health Status/Quality of Life Score (Change from Baseline)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"253"}],"units":"Participants"}],"description":"QLQ-C30 has 30 questions and scores range from 0-100 after a linear transformation. Questions are combined to produce symptom scales, individual symptom items, functional scales, and global health status (GHS)/quality of life (QoL).\n\nPositive change from baseline scores on the GHS/QoL and functioning scales indicate improvement on health status/function, and negative change scores on symptom scales/items represent less symptom severity/improvement on symptom status.\n\nThe score values calculated by averaging across patients overall mean across all visits. The analysis was performed using a MMRM analysis on the change from baseline in the score at each visit, including subject (random effect), treatment, visit (fixed effect \\& repeated measure) and treatment by visit interaction as explanatory variables, with the baseline score as a covariate along with the baseline score by assessment interaction.","dispersionType":"95% Confidence Interval","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Full Analysis Set, includes all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months after the first patient is randomized.","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30) (Randomized Component)","type":"SECONDARY","unitOfMeasure":"Scores on a Scale"}